Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine filed with FDA for emergency use authorisation as third 3-microgram dose in COVID-19
Pfizer announced that the companies have submitted an application to the FDA for emergency use authorisation (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-microgram dose in the three-dose primary series for children 6 months through 4 years of age
With the high level of respiratory illnesses currently circulating among children under 5 years of age, updated COVID-19 vaccines may help prevent severe illness and hospitalization.
If authorized, children in this age group would receive a primary series consisting of two 3-microgram doses of the original Pfizer-BioNTech COVID-19 Vaccine followed by a third 3-microgram dose of the Omicron BA.4/BA.5-adapted bivalent vaccine. An application to extend Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine marketing authorization in the EU to include children ages 6 months through 4 years is under discussion with the European Medicines Agency (EMA).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins